Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCX in Locally Advanced or Metastatic Nasopharyngeal Carcinoma
NCT02360501Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2008
- Primary completion
- Mar 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Response Rate at 6 months. Started Jan 2008; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02360501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360501.